Seminars in Cardiothoracic and Vascular Anesthesia

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to browse AJSM online!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Landis, R. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Landis, R. C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Seminars in Cardiothoracic and Vascular Anesthesia, Vol. 6, No. 4, 307-312 (2002)
DOI: 10.1177/108925320200600405

Aprotinin: Antithrombotic and Vasoactive Mechanisms of Action

R. Clive Landis, PhD

Cardiovascular Medicine Unit, Faculty of Medicine, Imperial College, Hammersmith Hospital, London W12 ONN, UK

Aprotinin is a serine protease inhibitor that has been in clinical use since the late 1980s to reduce blood loss in patients undergoing cardiopulmonary bypass surgery. Its hemostatic mechanism of action is mediated predominantly through inhibition of plasmin, thus exerting a net antifibrinolytic effect. Compared to other antifibrinolytics, however, aprotinin provides an additional patient benefit at the level of improved platelet function and diminished inflammatory response to bypass. Recent work on platelets has identified a cell-associated target for aprotinin: the thrombin-receptor, protease-activated receptor 1. Selective blockade of the protease-activated receptor 1 limits thrombin-induced activation and consequent "exhaustion" of platelets in the bypass circuit, while maintaining the hemostatic activity of platelets in the pericardial cavity in response to nonproteolytic agonists, such as collagen, adenosine diphosphate and epinephrine. While no specific cellular receptors have as yet been identified to explain the antiinflammatory and vasoactive properties of aprotinin, awareness is growing that serine protease-sensitive receptors belonging to the protease-activated receptor family (1-4) may represent important aprotinin targets, since these receptors are expressed by all major cells of the vasculature and act as sensors of the coagulation, inflammatory and vasoactive pathways activated by major surgery or trauma. The possibility is discussed that endothelial protease-activated receptor 2, whose natural ligands are trypsin, tryptase and the ternary tissue factor-Vlla-Xa complex, may be targeted by aprotinin.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?